Cytomegalovirus antigen-specific T cell

Cytomegalovirus antigen-specific T cells are immune cells (T lymphocytes) that specifically recognize and respond to peptides derived from human cytomegalovirus (HCMV) antigens presented by major histocompatibility complex (MHC) molecules on infected cells[5][7]. These include both CD8^+ cytotoxic T lymphocytes (CTLs), which kill infected target cells, and CD4^+ helper T cells, which provide help to CD8^+ cells and coordinate broader immune responses[2][9]. The immunodominant CMV antigens most frequently targeted include pp65 and IE-1 proteins[7]. CMV-specific T cells play a central role in controlling primary CMV infection and preventing viral reactivation, especially after bone marrow or organ transplantation, where endogenous immunity may be suppressed or insufficient. In clinical practice, ex vivo expanded CMV-specific T cells are used in adoptive cell therapies to restore antiviral immunity in immunocompromised patients. These T cells are defined by their capacity to release cytokines (typically interferon-γ) or express activation markers in response to CMV antigen stimulation, and are typically assessed by flow cytometry or cytokine release assays using CMV peptide pools. The molecular identity of a "CMV antigen-specific T cell" is not a single gene or protein product but rather a cell population defined by antigen specificity, phenotypic markers, and functional assays[7][4].\n\nNote:\n- This entry is considered "incorrect" as a canonical target entity because it refers to a *cell population defined by antigen specificity* rather than a unique molecule, receptor, or protein. It cannot be mapped directly to a specific molecular entity or gene product, nor does it fit standard target classifications like "enzyme" or "receptor."

Other names

CMV-specific T cellHuman cytomegalovirus-specific T cellHCMV-specific T cellCMV antigen-specific T cell

Virus-infected cell recognition and killing via T cell receptor (TCR) engagement with antigen-MHC complexes[3][7] Cytokine secretion (e.g., interferon-γ) to enhance antiviral defense[4][9] Adoptive cell therapy (transfer of ex vivo expanded antigen-specific T cells to patients)[7]